Skip to main content

Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference

Written by Customer Service on . Posted in Public Companies.

GAITHERSBURG, Md., Dec. 11, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of Altimmune will give an oral presentation on ALT-801, the Company’s novel GLP-1/Glucagon dual receptor agonist in development for the treatment of non-alcoholic steatohepatitis (NASH.) Dr. Harris will also participate on a panel discussion on NASH treatments. The presentations will take place at the 4thAnnual NASH Summit 2020 Digital Conference, which is being held December 15-18, 2020.
Details for the oral presentation are as follows:Details for the panel discussion are as follows:
A copy of Dr. Harris’ presentation and poster will be accessible on the Events section of the Altimmune website.
About the 4thAnnual NASH Summit 2020 Digital ConferenceThe digital 4th Annual NASH Summit 2020 Digital Conference is committed to delivering industry’s best opportunity to gain high-quality insights and connections expected at an in-person event in a format designed to maximize knowledge-sharing and networking without the need to travel. With an audience exclusively working on NASH drug development, the NASH Summit provides the latest insights from regulators, thought leaders, discovery scientists, leading clinical trial organizers, and translational and biomarker experts in the translational drug development and biomarker development.About ALT-801ALT-801 is a novel peptide-based dual GLP-1/glucagon receptor agonist that is designed to treat the obesity and metabolic dysfunction that causes NASH. As the most severe form of non-alcoholic fatty liver disease, or NAFLD, NASH involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid metabolites, and inflammation, resulting ultimately in fibrosis (cirrhosis) or liver cancer. Altimmune believes the treatment of obesity is the cornerstone of treating NASH and the principal morbidities of NASH. As observed in a well-established preclinical model of the disease, ALT-801 was capable of inducing significantly greater weight loss compared to semaglutide, a GLP-1 receptor agonist, along with significantly greater decreases in liver fat, plasma ALT, and other markers of NASH. ALT-801 is currently in Phase 1 development with initial data readouts expected during Q2 2021.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.Investor Contacts:Stacey Jurchison
Sr. Director, Investor Relations
Phone: 410-474-8200
sjurchison@altimmune.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.